Metabolic imaging using hyperpolarized (13)C‐pyruvate to assess sensitivity to the B‐Raf inhibitor vemurafenib in melanoma cells and xenografts

Nearly all melanoma patients with a BRAF‐activating mutation will develop resistance after an initial clinical benefit from BRAF inhibition (BRAFi). The aim of this work is to evaluate whether metabolic imaging using hyperpolarized (HP) (13)C pyruvate can serve as a metabolic marker of early respons...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Cell Mol Med
Autores principales: Acciardo, Stefania, Mignion, Lionel, Lacomblez, Estelle, Schoonjans, Céline, Joudiou, Nicolas, Gourgue, Florian, Bouzin, Caroline, Baurain, Jean‐François, Gallez, Bernard, Jordan, Bénédicte F.
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6991684/
https://ncbi.nlm.nih.gov/pubmed/31833658
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.14890
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares